Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the ...

The startup is developing macrocyles, which share strengths of both small molecules and biologics, as oral medicines against ...

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

By the end of March, the regulator could clear a highly anticipated pain drug from Vertex and a heart drug that’s critical to Alnylam’s future.

Expected readouts in diabetes, cancer and depression headline a series of study results that could help the biotechnology ...

The well-funded biotech lost most of its value after its drug flunked a late-stage trial. One analyst described the results ...

Happy New Year! We hope you had a restful holiday; If you took a break from keeping up with biotech news, we’ve got you covered with a brief rundown of the most important updates from the past week ...

DiveWire guarantees visibility for your news announcements through instant distribution to BioPharma Dive’s audience and its 176,000 newsletter subscribers for 21 days.